Anti-Tumor Immunity in Solid-Organ Transplant Recipients
Cancers · 11.04.2026 · 18 (8) · 1216
DOI: 10.3390/cancers18081216 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 11.04.2026. Verfasst von Jeffrey Sum Lung Wong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China. Die Arbeit nennt 253 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Solid-organ transplant (SOT) recipients have an increased risk of malignancies and poor oncological prognosis compared to the general population. A central reason for both is that various factors unique to transplantation coalesce to dampen anti-tumor immunity. These include graft or immunosuppressive therapy-related T-cell dysfunction, microenvironmental changes in grafts due to ischemic/reperfusion injuries peri-transplant and comorbidities such as metabolic syndrome. Both innate and adaptive immunity are heavily implicated in cytotoxicity effected by systemic therapeutic agents, not just immune checkpoint inhibitors (ICIs) but also conventional chemotherapy and targeted therapies. Hence, impaired anti-tumor immunity may also affect the treatment efficacy of these agents. Generally, clinical data for systemic therapies in transplant recipients is constrained to retrospective and heterogenous case reports and series only, with a low level of evidence and significant risk of bias. For ICIs, the efficacy in SOT recipients is relatively well preserved in cutaneous squamous cell carcinomas but seems diminished in other tumor types compared to non-transplant recipients. Data for other agents are limited, but the efficacies of chemotherapy in SOT recipients with colorectal cancer and sorafenib/lenvatinib in LT recipients with recurrent hepatocellular carcinoma seem preserved. Given the prevailing trend of broadening the use of transplantation in patients with cancer, further clinical and translational studies to develop strategies to enhance anti-tumor immunity while ensuring graft preservation are urgently needed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.
- Centre of Cancer Medicine, The University of Hong Kong, Hong Kong, China.
- Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.
ORCID-Profile: Desmond Yap, Thomas Yau
Zitieren
APA
Wong, J. S. L., Li, K. H. L., Li, B., Leung, R., Yap, D., Chan, A., Cheung, T. T., & Yau, T. (2026). Anti-Tumor Immunity in Solid-Organ Transplant Recipients. Cancers, 18(8), 1216. https://doi.org/10.3390/cancers18081216
Vancouver
Wong JSL, Li KHL, Li B, Leung R, Yap D, Chan A, et al. Anti-Tumor Immunity in Solid-Organ Transplant Recipients. Cancers. 2026;18(8):1216. doi:10.3390/cancers18081216
BibTeX
@article{Wong2026,
author = {Wong, Jeffrey Sum Lung and Li, Karen Hoi Lam and Li, Bryan and Leung, Roland and Yap, Desmond and Chan, Albert and Cheung, Tan-To and Yau, Thomas},
title = {Anti-Tumor Immunity in Solid-Organ Transplant Recipients},
journal = {Cancers},
year = {2026},
volume = {18},
number = {8},
pages = {1216},
doi = {10.3390/cancers18081216}
}
EUVIMED